Journal of Hepatology and Gastrointestinal disorders

OPEN ACCESS Freely available online

Commentary

A Treatment Approach for Reversing Liver Fibrosis by Targeting Matrix Metalloproteinases and TIMPs

Frank Barnes*

Department of Hepatology, University of Sao Paulo, Sao Paulo, Brazil

ABOUT THE STUDY

Liver fibrosis is a wound-healing response of the liver to chronic injury. It is characterized by the excessive accumulation of extracellular matrix proteins, particularly collagen, in the liver. The process begins when hepatocytes, the main functional cells of the liver, are damaged by various causes such as viral infections, alcohol abuse, Non-Alcoholic Fatty Liver Disease (NAFLD), and other chronic liver conditions. This damage leads to the activation of resident liver cells, primarily Hepatic Stellate Cells (HSCs), which play a pivotal role in fibrogenesis. In a healthy liver, these cells exist in a quiescent state and store vitamin A. However, upon liver injury, they undergo a process known as activation, transitioning into myofibroblast-like cells that proliferate and produce large amounts of extracellular matrix components, such as collagen.

Once activated, HSCs start to secrete pro-fibrotic cytokines, including Transforming Growth Factor-Beta (TGF-β), a key factor in fibrogenesis. TGF-β stimulates HSCs to further increase collagen production and inhibits enzymes responsible for collagen degradation, such as Matrix Metallo Proteinases (MMPs). Simultaneously, Tissue Inhibitors of Metallo Proteinases (TIMPs) are upregulated, further reducing the breakdown of the accumulated extracellular matrix. This imbalance between production and degradation of the extracellular matrix leads to its excessive deposition, which disrupts the normal liver architecture and impairs liver function.

Another key cell type involved in liver fibrosis is the Kupffer cell, the unique macrophage of the liver. Kupffer cells become activated in response to liver injury and release a variety of inflammatory mediators, such as Tumor Necrosis Factor-Alpha (TNF-α) and Inter Leukin-1 (IL-1), which further perpetuate inflammation and fibrosis. In addition to Kupffer cells, recruited monocyte-derived macrophages are attracted to the injured liver by chemokines and contribute to the fibro genic process by secreting additional pro-inflammatory and pro-fibrotic factors.

Chronic liver injury also leads to the activation of other immune cells, including neutrophils, lymphocytes, and dendritic cells, which collectively contribute to a persistent state of inflammation This chronic inflammatory condition creates a cycle where hepatocyte injury leads to the activation of immune and fibro genic cells, which in turn cause further hepatocyte damage and fibrosis. This self-perpetuating cycle can lead to progressive liver fibrosis and eventually cirrhosis, a condition characterized by severe scarring of the liver, impaired liver function, and an increased risk of liver cancer.

The liver has a unique ability for regeneration, and under certain conditions, liver fibrosis can be reversed, especially if the underlying cause of the liver injury is removed or treated early enough. The reversal of liver fibrosis involves the inactivation or apoptosis of activated HSCs, degradation of the accumulated extracellular matrix, and restoration of normal liver formation. Several mechanisms contribute to the reversal of liver fibrosis.

One key mechanism is the deactivation of HSCs. When the source of liver injury is removed, the pro-fibrotic signals that maintain HSC activation diminish. As a result, activated HSCs can revert to a more quiescent state or undergo apoptosis, leading to a reduction in extracellular matrix production. The deactivation of HSCs is mediated by several signaling pathways, including those involving peroxisome Proliferator-Activated Receptor-Gamma (PPAR-γ), a nuclear receptor that regulates lipid metabolism and has anti-fibrotic effects. Activation of PPAR-γ has been shown to promote the deactivation of HSCs and reduce collagen production.

Another important mechanism for fibrosis reversal is the degradation of the excess extracellular matrix. Matrix Metallo Proteinases (MMPs), particularly MMP-1, MMP-8, and MMP-13, are enzymes that break down collagen and other matrix components. During fibrosis resolution, the expression and activity of these MMPs are upregulated, while the levels of TIMPs are reduced, allowing for increased matrix degradation. Kupffer cells and recruited macrophages play a role in fibrosis reversal by switching from a pro-inflammatory, pro-fibrotic phenotype to a pro-resolution, anti-fibrotic phenotype. This phenotypic switch is associated with the production of anti-inflammatory cytokines such as Inter Leukin-10 (IL-10) and Transforming Growth Factor-Beta 1 (TGF-β1), which promote matrix degradation and tissue repair.

Correspondence to: Frank Barnes, Department of Hepatology, University of Sao Paulo, Sao Paulo, Brazil, E-mail: barnesfrank88@gmail.com

Received: 19-Aug-2024, Manuscript No. JHGD-24-35618; **Editor assigned:** 22-Aug-2024, PreQC No. JHGD-24-35618 (PQ); **Reviewed:** 06-Sep-2024, QC No. JHGD-24-35618; **Revised:** 13-Sep-2024, Manuscript No. JHGD-24-35618 (R); **Published:** 20-Sep-2024, DOI: 10.35248/2475-3181.24.10.323

Citation: Barnes F (2024). A Treatment Approach for Reversing Liver Fibrosis by Targeting Matrix Metalloproteinases and TIMPs. J Hepatol Gastroint Dis.10:323.

Another important factor in the reversal of liver fibrosis is the liver's inherent regenerative capacity. Following the removal of chronic injury, hepatocytes have the ability to proliferate and restore normal liver structure. This regenerative response is processed by several growth factors, including Hepatocyte Growth Factor (HGF), Epidermal Growth Factor (EGF), and Insulin-like Growth Factor (IGF), which promotes hepatocyte proliferation and survival. The regeneration of hepatocytes helps replace damaged or lost liver cells, which can reduce the need for further activation of HSCs and fibrogenesis.